Intensity Therapeutics updates preliminary financial slide
Intensity Therapeutics, Inc. furnished an update to its investor materials, providing an unaudited Financial Highlights Slide through December 31, 2025.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Intensity Therapeutics, Inc. furnished an update to its investor materials, providing an unaudited Financial Highlights Slide through December 31, 2025. The slide, dated March 4, 2026, is available on the company’s investor relations website and is also attached as an exhibit.
The figures in this slide are preliminary and subject to completion of financial closing procedures and management review, so they may differ materially from the final results reported in the company’s year-end financial statements.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Intensity Therapeutics (INTS) disclose in this 8-K filing?
Intensity Therapeutics furnished an updated Financial Highlights Slide through December 31, 2025. The unaudited, preliminary figures appear in its investor presentation, available on the investor relations website and attached as Exhibit 99.1 to this 8-K report for informational purposes.
Are the Intensity Therapeutics (INTS) financial figures in the slide final?
No, the figures in the Financial Highlights Slide are unaudited and preliminary. They remain subject to financial closing procedures and management review, so the final numbers in Intensity Therapeutics’ year-end financial statements may differ materially from those currently presented.
Where can investors find the updated Intensity Therapeutics (INTS) Financial Highlights Slide?
Investors can access the updated Financial Highlights Slide through December 31, 2025 on Intensity Therapeutics’ investor relations website. The same slide, dated March 4, 2026, is also furnished as Exhibit 99.1 to this 8-K report for reference.
Does the Intensity Therapeutics (INTS) 8-K include audited financial statements?
The 8-K does not include audited financial statements. It furnishes an updated Financial Highlights Slide with unaudited, preliminary data that may change after completion of financial closing procedures and management’s review for the year ended December 31, 2025.
Is the Intensity Therapeutics (INTS) Financial Highlights Slide considered filed with the SEC?
The Financial Highlights Slide furnished as Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act. It is provided for informational use and is only incorporated by reference into other filings if specifically stated there.
What exhibits accompany the Intensity Therapeutics (INTS) 8-K?
The 8-K includes Exhibit 99.1, which is the Financial Highlights Slide dated March 4, 2026, and Exhibit 104, the cover page interactive data file formatted in Inline XBRL, satisfying current SEC technical disclosure requirements for electronic filings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 5, 2026
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class: | Trading Symbol(s): | Name of Exchange on Which Registered: | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
From time to time, Intensity Therapeutics, Inc. (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On March 5, 2026, the Company updated the Financial Highlights Slide through December 31, 2025 (the “Slide”) of its investor presentation, which is available on the Investor Relations section of the Company’s website at https://ir.intensitytherapeutics.com. The Slide is also furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02.
All figures in the Slide are unaudited and preliminary and are subject to the completion of financial closing procedures, including management’s reviews. As a result, this amount may differ materially from the amount that will be reflected in the Company’s financial statements as of and for the year ended December 31, 2025.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Financial Highlights Slide, dated March 4, 2026 | |||||||
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL). | |||||||
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 5, 2026
| Intensity Therapeutics, Inc. | |||||||||||
| By: | /s/ Lewis H. Bender | ||||||||||
| Name: | Lewis H. Bender | ||||||||||
| Title: | Chief Executive Officer | ||||||||||
[Signature Page to the Form 8-K]
2
Exhibit 99.1
Updated as of March 5, 2026
